News

Here’s a concise 130‑word English summary based on the document: --- Tirzepatide is a dual GIP/GLP‑1 receptor agonist developed by Eli Lilly for diabetes, NASH, and chronic weight management, with a 116.7‑hour half‑life and up to 21% weight reduction in trials. Its 39‑amino‑acid peptide backbone includes two non‑natural amino‑isobutyric acid residues and a side chain at Lys20. To overcome the low yield and purity issues of conventional solid‑phase synthesis for large peptides, Lilly adopted a hybrid SPPS/LPPS strategy. Four high‑purity fragments (97.5–99.5%) were synthesized via SPPS, then sequentially coupled in liquid phase through a four‑step process. Finally, nanofiltration effectively removes low‑molecular‑weight impurities (e.g., DBF, DEA, PyO‑related byproducts) while retaining the target peptide. This integrated approach enables scalable, robust manufacturing with simplified operations, supporting both R&D and commercial supply.

Trofinetide (CAS:853400-76-7), co-developed by Neuren and Acadia Pharmaceuticals, gained FDA approval in March 2023 for Rett syndrome in patients aged 2 and above. As a synthetic GPE tripeptide analog, it targets MeCP2 gene mutation-induced neurodevelopmental defects. Its scalable synthesis uses in-situ silane protection to avoid degradation and column purification, with four high-yield steps ending in Pd/C deprotection. The final API is isolated by spray drying, offering a practical production route for this rare disease therapeutic.

Cagrilintide is a novel long-acting acylated amylin analog and a cyclic 38-amino-acid polypeptide with dual activity at the amylin and calcitonin receptors. It reduces food intake and body weight, delays gastric emptying, and improves glycemic control, showing promise for obesity, diabetes, and metabolic syndrome. The described preparation method employs Fmoc solid-phase peptide synthesis incorporating three pseudoproline dipeptides to mitigate aggregation, followed by cleavage, liquid-phase cyclization, and HPLC purification. This process yields high-purity Cagrilintide (>99.0%) with each single impurity below 0.1%, achieving an overall yield of approximately 32%. The method is robust, scalable, and suitable for industrial production, providing a reliable route for research and commercial applications. For intermediates and impurity standards, Cosperpharm offers comprehensive support from development to manufacturing.

Delgocitinib Cream is the world’s first topical pan‑JAK inhibitor developed for treating chronic hand eczema (CHE) in adults. It blocks the JAK‑STAT pathway by inhibiting JAK1, JAK2, JAK3, and TYK2, thereby suppressing inflammatory responses central to disease pathogenesis. Approved in the EU, UK, Switzerland, and UAE for moderate‑to‑severe CHE, its FDA approval was supported by two 16‑week phase 3 trials showing significantly higher rates of treatment success (IGA‑CHE 0/1 with ≥2‑point improvement) versus placebo (20–29% vs. 7–10%), alongside superior relief of pruritus and pain. Adverse events include local skin reactions, bacterial infections, and leukopenia, but overall incidence was low and comparable to placebo.

In nuclear medicine, chelators serve as the critical bridge connecting targeted ligands to radionuclides, and their chemical properties directly determine the labeling efficiency, in vivo stability, and pharmacokinetic characteristics of the drug conjugate. Chelators securely incorporate radioactive metal nuclides (e.g., ⁶⁸Ga, ¹⁷⁷Lu, ⁸⁹Zr, ²²⁵Ac) into the drug molecule within the biological environment; any instability-induced release of these nuclides may cause radiation damage to non-target tissues and lead to severe toxicity.

Brexpiprazole is an atypical antipsychotic approved for schizophrenia, major depressive disorder (adjunctive), and Alzheimer’s-related agitation. Its core Chinese patent expires in April 2026, opening the door for generic competition. The synthetic route features key steps: fluorinated nucleophilic substitution, benzothiophene formation via ethyl mercaptate–benzaldehyde reaction, Cu‑catalyzed Boc deprotection, and two nucleophilic substitutions with strict impurity control for intermediate 7. Compound 5 is proposed as a compliant starting material per ICH guidelines. Cosperpharm offers comprehensive support for process development, quality control, and regulatory documentation to help you accelerate your brexpiprazole program.